Tissue Regenix Group PLC Notice of Preliminary Results (9305G)
March 09 2015 - 10:05AM
UK Regulatory
TIDMTRX
RNS Number : 9305G
Tissue Regenix Group PLC
09 March 2015
Tissue Regenix Group plc
("Tissue Regenix" or "the Company")
Notice of Preliminary Results
YORK, 9(th) March 2015 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix"), the regenerative medical devices company,
announces that it will publish its unaudited preliminary results
for the year ended 31 January 2015, on Monday 11(th) May 2015.
For Further Information
Tissue Regenix Group Plc:
Antony Odell
Ian Jefferson +44 19 0443 5176
Jefferies International
Ltd:
Simon Hardy
Harry Nicholas +44 20 7029 8000
Tulchan Communications:
Tom Buchanan
Victoria Huxster +44 207 353 4200
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREALDNEEASEFF
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024